Malignant Pleural Mesothelioma - Lilly Announces Phase II Results for ALIMTA(R) in First-Line Metastatic Breast Cancer Trial

Lilly Announces Phase II Results for ALIMTA(R) in First-Line Metastatic Breast Cancer Trial
ATLANTA, June 4 /PRNewswire-FirstCall/ -- At t

CuraGen and TopoTarget Announce Initiation of NCI-sponsored Phase II Clinical Trial with PXD101 for Mesothelioma
CuraGen Corporation and TopoTarget A/S announced today the initiation of patient dosing in a Phase II clinical trial evaluating the activity of PXD101, a small molecule histone deacetylase inhibitor, for the treatment of mesothelioma.